153 related articles for article (PubMed ID: 38357673)
1. Prognostic value of preoperative serum ferritin in hepatocellular carcinoma patients undergoing transarterial chemoembolization.
Fan M; Niu T; Lin B; Gao F; Tan B; Du X
Mol Clin Oncol; 2024 Mar; 20(3):22. PubMed ID: 38357673
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of serum HIF-1α change following transarterial chemoembolization in hepatocellular carcinoma.
Lin ZH; Jiang JR; Ma XK; Chen J; Li HP; Li X; Wu XY; Huang MS; Lin Q
Clin Exp Med; 2021 Feb; 21(1):109-120. PubMed ID: 33037574
[TBL] [Abstract][Full Text] [Related]
3. Identifying optimal candidates of transarterial chemoembolization (TACE)
Zhao S; Dou W; Fan Q; Hu J; Li H; Zhang X; Zhang Q; Liu L
Ann Transl Med; 2020 May; 8(9):587. PubMed ID: 32566614
[TBL] [Abstract][Full Text] [Related]
4. Exploring the clinical value of preoperative serum gamma-glutamyl transferase levels in the management of patients with hepatocellular carcinoma receiving postoperative adjuvant transarterial chemoembolization.
Ke Q; Xiang F; Xiao C; Huang Q; Liu X; Zeng Y; Wang L; Liu J
BMC Cancer; 2021 Oct; 21(1):1117. PubMed ID: 34663242
[TBL] [Abstract][Full Text] [Related]
5. Tumor burden score as a new prognostic marker for patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
Ho SY; Liu PH; Hsu CY; Ko CC; Huang YH; Su CW; Lee RC; Tsai PH; Hou MC; Huo TI
J Gastroenterol Hepatol; 2021 Nov; 36(11):3196-3203. PubMed ID: 34159651
[TBL] [Abstract][Full Text] [Related]
6. Low Psoas-Muscle index is associated with decreased survival in hepatocellular carcinoma treated with transarterial chemoembolization.
Zhang JX; Yan HT; Ding Y; Liu J; Liu S; Zu QQ; Shi HB
Ann Med; 2022 Dec; 54(1):1562-1569. PubMed ID: 35639492
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Factors for Survival After Transarterial Chemoembolization Combined with Sorafenib in the Treatment of BCLC Stage B and C Hepatocellular Carcinomas.
Ni JY; Kong J; Sun HL; Chen YT; Luo JH; Wang WD; Chen D; Jiang XY; Xu LF
Acad Radiol; 2018 Apr; 25(4):423-429. PubMed ID: 29198946
[TBL] [Abstract][Full Text] [Related]
8. The C-Reactive Protein to Albumin Ratio Is an Independent Prognostic Factor in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: A Large Cohort Study.
Li J; Yang S; Li Y; Li C; Xia Y; Zhu S; Xia J
Cardiovasc Intervent Radiol; 2022 Sep; 45(9):1295-1303. PubMed ID: 35835873
[TBL] [Abstract][Full Text] [Related]
9. Impact of serum vascular endothelial growth factor on prognosis in patients with unresectable hepatocellular carcinoma after transarterial chemoembolization.
Guo JH; Zhu X; Li XT; Yang RJ
Chin J Cancer Res; 2012 Mar; 24(1):36-43. PubMed ID: 23359473
[TBL] [Abstract][Full Text] [Related]
10. Alterations of telomere length and mtDNA copy number are associated with overall survival in hepatocellular carcinoma patients treated with transarterial chemoembolization.
Bao D; Ba Y; Zhou F; Zhao J; Yang Q; Ge N; Guo X; Wu Z; Zhang H; Yang H; Wan S; Xing J
Cancer Chemother Pharmacol; 2016 Oct; 78(4):791-9. PubMed ID: 27558242
[TBL] [Abstract][Full Text] [Related]
11. Validation of the six-and-twelve criteria among patients with hepatocellular carcinoma and performance score 1 receiving transarterial chemoembolization.
Wang ZX; Li J; Wang EX; Xia DD; Bai W; Wang QH; Yuan J; Li XM; Niu J; Yin ZX; Xia JL; Fan DM; Han GH
World J Gastroenterol; 2020 Apr; 26(15):1805-1819. PubMed ID: 32351295
[TBL] [Abstract][Full Text] [Related]
12. Preoperative transarterial chemoembolization for hepatocellular carcinoma.
Kishi Y; Saiura A; Yamamoto J; Koga R; Seki M; Morimura R; Yoshioka R; Kokudo N; Yamaguchi T
Hepatogastroenterology; 2012 Oct; 59(119):2295-9. PubMed ID: 23435144
[TBL] [Abstract][Full Text] [Related]
13. Preoperative Versus Postoperative Transarterial Chemoembolization on Prognosis of Large Hepatocellular Carcinoma.
Wang X; Yuan Y; Wang J; Liu Z; Chen M; Zhou Q; Zhou Z
J Cancer; 2021; 12(20):6231-6241. PubMed ID: 34539896
[No Abstract] [Full Text] [Related]
14. Validation and prognostic value of EZ-ALBI score in patients with intermediate-stage hepatocellular carcinoma treated with trans-arterial chemoembolization.
Ananchuensook P; Sriphoosanaphan S; Suksawatamnauy S; Siripon N; Pinjaroen N; Geratikornsupuk N; Kerr SJ; Thanapirom K; Komolmit P
BMC Gastroenterol; 2022 Jun; 22(1):295. PubMed ID: 35701739
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Postoperative Adjuvant Transcatheter Arterial Chemoembolization in Hepatocellular Carcinoma Patients with Mesenchymal Circulating Tumor Cell.
Zhang J; Peng H; Wang B; Luo L; Cheng Y; He G; Tang Y; Pan M
J Gastrointest Surg; 2021 Jul; 25(7):1770-1778. PubMed ID: 32748340
[TBL] [Abstract][Full Text] [Related]
16. Transarterial Chemoembolization versus Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma after Resection within Barcelona Clinic Liver Cancer Stage 0/A: A Retrospective Comparative Study.
Chen R; Gan Y; Ge N; Chen Y; Wang Y; Zhang B; Wang Y; Ye S; Ren Z
J Vasc Interv Radiol; 2016 Dec; 27(12):1829-1836. PubMed ID: 27553917
[TBL] [Abstract][Full Text] [Related]
17. Transarterial chemoembolization combined with recombinant human adenovirus type 5 H101 prolongs overall survival of patients with intermediate to advanced hepatocellular carcinoma: a prognostic nomogram study.
He CB; Lao XM; Lin XJ
Chin J Cancer; 2017 Jul; 36(1):59. PubMed ID: 28728568
[TBL] [Abstract][Full Text] [Related]
18. Inversed albumin-to-globulin ratio and underlying liver disease severity as a prognostic factor for survival in hepatocellular carcinoma patients undergoing transarterial chemoembolization.
Li J; Li Z; Hao S; Wang J; Chen W; Dai S; Hou Z; Chen B; Zhang Y; Liu D
Diagn Interv Radiol; 2023 May; 29(3):520-528. PubMed ID: 36992824
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant Transarterial chemoembolization does not influence recurrence-free or overall survival in patients with combined hepatocellular carcinoma and Cholangiocarcinoma after curative resection: a propensity score matching analysis.
Liu WR; Tian MX; Tao CY; Tang Z; Zhou YF; Song SS; Jiang XF; Wang H; Zhou PY; Qu WF; Fang Y; Ding ZB; Zhou J; Fan J; Shi YH
BMC Cancer; 2020 Jul; 20(1):642. PubMed ID: 32650743
[TBL] [Abstract][Full Text] [Related]
20. Baseline quantitative hepatitis B core antibody could strongly predict survival for patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
Yuan G; Zhou Y; Zhang H; Wang J; Yang N; Guo Y; Yang D; Zhou Y
Int J Clin Exp Med; 2015; 8(8):13524-31. PubMed ID: 26550290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
